Andy Nematalla Highlights New Approaches to Closing the Commercialization Gap in Life Sciences

Introduction

The world’s top 2,000 companies spent more than $1.35 trillion on R&D in 2024, but only 20% of resulting patents show clear signs of commercialization, according to the European Commission’s EU Industrial R&D Investment Scoreboard. In life sciences, the gap is even more stark. Andy Nematalla, a global investment executive with two decades scaling companies across technology, content, and emerging markets, calls this the missing link. “Investors increasingly evaluate companies through a commercialization lens,” Andy Nematalla writes.

“The transition from innovation to commercialization, followed by monetization and scale, determines whether a company becomes a valuable enterprise or simply remains an interesting concept.” This article applies Andy Nematalla‘s commercialization framework to the specific challenge facing biotech and life sciences leaders: converting clinical science into durable commercial value.

A Pipeline-Heavy and Launch-Light Industry

Biotech is structurally extraordinary at producing science and structurally weak at producing companies. GlobalData’s database showed 8,684 investigational drugs under active development by emerging pharmaceutical companies in April 2025, with 46% in preclinical and 22% in discovery. Yet only 6.7% of Phase I drugs are ultimately approved per Citeline’s 10-year transition data and Phase II remains the killer, with just 28% of programs clearing it.

McKinsey reports that first-time biotech launches accounted for roughly 40% of new molecular entities submitted for FDA approval between 2018 and 2023, but only 20-30% exceeded launch expectations versus 40-50% for established companies. PharmExec adds that nearly 90% of biotech startups ultimately fail, and only 28% of first-time product launches exceed analyst pre-launch forecasts.

Build a Commercial Engine Before You Need One

Andy Nematalla‘s central argument applies here: “companies must move beyond building products/services but deliver a commercial product/service together with implementing systems, capture demand, and transform success to sustained growth.” For a biotech, that means designing the launch infrastructure during Phase II. The cost of getting this wrong is now measurable. PharmExec reports biotech bankruptcies hit a 10-year peak in 2023, and Phase I trials now cost an average of $7.1 million and run up to two years. Capital that arrives without a commercialization plan accelerates failure rather than preventing it.

Andy Nematalla’s Commercialization Disciplines, Applied to Biotech

1. Treat Commercialization as a Cultural Transformation – Andy Nematalla writes that “the skills required to build a product are not the same as those required to scale an organization.” In biotech, this means founders must intentionally hand over cross-functional commercial operations to leaders who have launched before. PharmExec frames this as the move from “two-variable equations to more complex organizations,” identifying it as the most common point of failure for promising clinical-stage companies.
2. Sequence Indications Like Verticals – Andy Nematalla advocates evidence-based sequencing of expansion. McKinsey’s data shows that first-time launchers with assets in white-space indications are 1.7x more likely to exceed expectations than in indications with three or more competitors. Companies with multiple assets exceed the S&P 500 Biotech Index roughly 50% of the time, versus 30% for single-product peers. Every new indication should be an extension of a proven commercial model.
3. Use Partnerships as Distribution – Andy Nematalla‘s puts partnerships at the center of modern growth: “a technology startup may possess breakthrough innovation but lack distribution infrastructure, while a multinational corporation may have global reach but require access to new technologies.” Biotech mirrors exactly this. In 2024, Gilead acquired CymaBay Therapeutics for its Phase III PPARδ agonist, and Bristol Myers Squibb acquired Karuna Therapeutics for its neuroscience portfolio.
4. Build for Pipeline Resilience – Andy Nematalla‘s framework warns against single-bet thinking. Blackstone Life Sciences’ BXLS platform reports an 86% Phase 3 clinical franchise success rate built on pipeline depth and selectivity.

Conclusion

The biotech industry faces an estimated $320 billion patent cliff by 2030, making commercial discipline the difference between a one-product company and a durable enterprise. Andy Nematalla‘s framing translates a biotech with two well-launched assets in white-space indications will outvalue a biotech with one blockbuster running into a generic cliff. For life sciences leaders, the operational implication is to build the commercial system before the science needs it. Leadership augmentation in Phase II, pricing and market-access workstreams initiated 24-36 months pre-launch, and partnership architecture designed for distribution rather than as a financing crutch. Andy Nematalla brings an investor’s lens to biotech’s R&D-to-commercial transition. To explore his published frameworks on turning innovation into sustainable commercial value, visit Andy Nematalla.

FAQs

What is the “commercialization gap” Andy Nematalla refers to?

ANS: The commercialization gap is the structural distance between a technically validated innovation and a commercially deployed product. In life sciences specifically, only about 20% of patents from $1.35 trillion in annual R&D spending show signs of commercialization, and only 6.7% of Phase I drugs reach FDA approval. Andy Nematalla argues this gap is closed by operational alignment, partnerships, and disciplined commercial design.

Why do so few first-time biotech launchers exceed forecasts?

ANS: McKinsey’s data shows only 20-30% of first-time launchers exceed launch expectations, versus 40-50% for established players. The drivers are predictable. Weak commercial leadership relative to scientific leadership, single-asset risk concentration, and pipelines designed for FDA approval rather than market access.

How should biotech leaders use strategic partnerships, per Andy Nematalla’s framework?

ANS: Andy Nematalla frames partnerships as distribution accelerators. The best partnerships reduce customer acquisition cost, accelerate geographic expansion, leverage existing infrastructure, and enhance credibility through association. In biotech, this most often takes the form of co-commercialization, licensing, or strategic minority investment from larger pharma with regional or therapeutic-area expertise.

What does “verticalization” mean for a clinical-stage biotech?

ANS: Verticalization for biotech means concentrating commercial infrastructure in a therapeutic area where the company’s first launch creates organizational learning that the second and third assets can inherit. Rare diseases, where competition is structurally lower, allow first-time launchers to exceed expectations at roughly 40%.

When should a biotech start building its commercial engine?

ANS: According to PharmExec and the broader McKinsey biotech research, building during Phase II is now table-stakes. Companies that wait until BLA filing to hire commercial leadership routinely miss launch expectations. The 24-36 months between Phase II readout and approval is the window for pricing strategy, payer engagement, salesforce design, and partnership structuring.